http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8e137581ff28dcb69f5ab803a51fee99
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Maio |
| name | Michele Maio |
| given-name | Michele |
| organization-name | Cancer Bioimmunotherapy Unit and Division of Anesthesia, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Via Pedemontana Occ.le, 12, Aviano, 33081 Italy Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy 1Department of Oncology, Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy.; 9NIBIT Foundation, Onlus, Italy.; 12University of Siena, Siena, Italy. 11University Hospital of Siena, Siena, Italy. Authors' Affiliations: 1Unit of Immunotherapy of Human Tumors, 2Unit of Clinical Epidemiology and Trial Organization, 3Melanoma and Sarcoma Unit, 4Immunohematology and Transfusion Division, and 5Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori; 6Microscopy and Image Analysis, Department of Neurosciences and Biotechnology, Università degli Studi di Milano, Milan; 7Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena; 8Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano; and 9Medical Oncology Unit, Istituto Oncologico Veneto-IRCCS, Padova, Italy; Authors' Affiliations: 1Unit of Immunotherapy of Human Tumors, 2Unit of Clinical Epidemiology and Trial Organization, 3Melanoma and Sarcoma Unit, 4Immunohematology and Transfusion Division, and 5Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori; 6Microscopy and Image Analysis, Department of Neurosciences and Biotechnology, Università degli Studi di Milano, Milan; 7Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena; 8Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano; and 9Medical Oncology Unit, Istituto Oncologico Veneto-IRCCS, Padova, Italy University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. Center for Immuno-Oncology, Department of Oncology, University Hospital of Siena, Siena, Italy. Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy Division of Medical Oncology & Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Strada delle Scotte 14, 53100 Siena, Italy. Center for Immuno‐Oncology, Medical Oncology and Immunotherapy University Hospital of Siena Siena Italy 3University of Siena, Siena, and Wim H.J. Kruit, Erasmus Medical Center, Rotterdam, the Netherlands; Stefan Suciu, European Organisation for Research and Treatment of Cancer Headquarters, Brussels; Jamila Louahed, Frédéric F. Lehmann, and Vincent G. Brichard, GlaxoSmithKline Biologicals, Rixensart, Belgium; Brigitte Dreno, Centre Hospitalier Universitaire (CHU); Laurent Mortier, Centre Hospitalier Régional Universitaire (CHRU), Lille; Caroline Robert and Alexander M.M. Eggermont, Institute Gustave Roussy; Thierry Dorval, Institut Curie,... Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. mmaio@cro.it Medical Oncology and Immunotherapy University Hospital of Siena Siena Italy Division of Medical Oncology and Immunotherapy University Hospital of Siena, Istituto Toscano Tumouri Siena Italy Center for Immuno‐Oncology University Hospital of Siena Italy; University of Siena Italy; NIBIT Foundation Onlus Siena Italy Istituto Toscano Tumori, University Hospital, Siena, Italy Center for Immuno-Oncology, University Hospital, Siena, Italy Department of Oncology, Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy 6Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy; Aviano, Italy 1Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy;; 2Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy; and From Gustave Roussy Cancer Campus Grand Paris, Villejuif (A.M.M.E., C.R.), Aix–Marseille University, Hôpital de La Timone, Marseille (J.-J.G.), Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Paris (C.L.), University Lille, INSERM Unité-1189, Centre Hospitalier Universitaire (CHU) Lille, Service de Dermatologie, Lille (L.M.), and CHU Lyon, Lyon (L.T.) — all in France; the Oncology Institute of Veneto–Istituto di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Istituto Nazionale... 1Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. Benjamin Weide, Annette Pflugfelder, Thomas K. Eigentler, Claus Garbe, Henning Zelba, Evelyna Derhovanessian, and Graham Pawelec, University Medical Center, University of Tübingen, Tübingen; Antje Sucker and Dirk Schadendorf, University Medical Center, Essen, Germany; Anna Maria Di Giacomo and Michele Maio, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Erik H.J.G. Aarntzen and I. Jolanda M. de Vries, Radboud University Medical Centre, Nijmegen, the Netherlands; and Petra Büttner,... Michele Maio, University Hospital of Siena, Siena; Vanna Chiarion-Sileni, Veneto Oncology Institute-Istituto Di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille; Luc Thomas, Lyon 1 University, Centre Hospitalier Lyon Sud, Pierre Bénite; Caroline Robert, Institute Gustave Roussy, Villejuif, France; Steinar Aamdal, Oslo University... Antoni Ribas, University of California Los Angeles, Los Angeles, CA; Richard Kefford, Westmead Institute for Cancer Research and Melanoma Institute Australia, University of Sydney at Westmead Hospital, Sydney, New South Wales; Grant A. McArthur, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Margaret A. Marshall, Jesus Gomez-Navarro, Bo Huang, and Dmitri Pavlov, Pfizer Global Research and Development, Groton, CT; Cornelis J.A. Punt, Radboud University Nijmegen Medical Center,... Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena; Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano (PN) 6Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. 6Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy;; 7Cancer Bio-Immunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy; and Center for Immuno-Oncology, University Hospital; NIBIT FoundationOnlus; Department of Emergency and Organ Transplantation, University of Siena, Siena, Italy From the Units of General Surgery 2, Immunotherapy of Human Tumors, Immunohematology and Blood Bank, Pathology, Diagnostic Radiology, and Pharmacy, Istituto Nazionale Tumori; Divisions of Surgery and Pathology, Istituto Europeo di Oncologia, Milan; Units of Cancer Biotherapy, Anesthesiology, and Surgery, Centro di Riferimento Oncologico, Aviano; Divisions of Medical Oncology and Surgery, Istituto Scientifico Tumori, Genoa; and Sigma Tau, i.f.r. S.p.A., Rome, Italy; Antigenics, Inc, Woburn, MA; and Center... Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Medical Sciences, Surgical and Neuroscience, 53100 Siena, Italy; Italian Network for Tumor Bio-Immunotherapy Foundation Onlus, 53100 Siena, Italy 9Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Italy. University of Siena and Center for Immuno-Oncology, University Hospital Le Scotte, Siena, Italy 1Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. 6Azienda Ospedaliera Universitaria Senese, Siena, Italy. Authors' Affiliations: 1Department of Dermatology, University Medical Center; 2Department of Internal Medicine II, Section for Transplantation Immunology and Immunohematology, University of Tübingen, Tübingen; 3German Cancer Research Center (DKFZ); 4German Cancer Consortium (DKTK), Heidelberg; 5Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen, Germany; 6Department of Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Italy; and 7Skin Cancer Research Group, School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Townsville, Australia From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille (J.-J.G.) — all in France; Netherlands Cancer Institute–Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center... The authors' affiliations are listed in the Appendix. 5Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. From the Department of Medical Oncology, Royal Marsden Hospital, London (J.L.), and South West Wales Cancer Institute, Singleton Hospital, Swansea (J.W.) — both in the United Kingdom; Melanoma Oncology Unit, Veneto Region Oncology Research Institute, Padua (V.C.-S.), Oncology of Melanoma Unit, European Institute of Oncology, Milan (P.F.F.), University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) — all in Italy; Division of Medical Oncology, University... Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy and Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy 1Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy;; 3Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy 1Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.; 2NIBIT Foundation Onlus, Genova, Italy. Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy Authors' Affiliations: 1Departments of Medicine, Surgery and Immunology, University of Pittsburgh, 2Biostatistics Department, Graduate School of Public Health, University of Pittsburgh and Biostatistics Facility, 3Department of Pathology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; 4Baylor Institute for Immunology Research, Dallas, Texas; 5Department of Gene and Cell Medicine, Immunology Institute, Mount Sinai School of Medicine, New York, New York; 6Department of Hematology & Immunobiology, Yale University, New Haven, Connecticut; 7ZellNet Consulting, Inc., Fort Lee, 8Discovery Medicine-Clinical Oncology, Bristol-Myers Squibb, Inc., Princeton, New Jersey; 9Cellular Technology Limited, Shaker Heights, Ohio; 10Department of Medicine (Hematology), Stanford University School of Medicine, 11Human Immune Monitoring Center, Institute for Immunity, Transplantation, and Infection, Stanford University Medical School, Stanford, 12BD Biosciences, San Jose, California; 13Applied and Developmenta 12Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy. From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.),... 5Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy;; 7Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy; and for the VIABLE Investigators Authors' Affiliations: 1Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; 2Bristol-Myers Squibb Company, Wallingford, Connecticut; 3Medical Oncology, The Angeles Clinic and Research Institute, Santa Monica, California; 4Department of Oncologic Sciences, University of South Florida, Tampa, Florida; 5Department of Dermatology, Saint-Louis Hospital, Paris, France; 6Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; 7Department of Dermatology, Medical University of Vienna, Vienna, Austria; 8Perceptive Informatics, Berlin, Germany; 9Medarex, Inc., Princeton, New Jersey; and 10Dana-Farber Cancer Institute, Boston, Massachusetts From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) — both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno... |
Incoming Links
Total number of triples: 303.